Skip to main content
P

PYC THERAPEUTICS LIMITED — Investor Relations & Filings

Ticker · PYC ISIN · AU000000PYC7 ASX Professional, scientific and technical activities
Open in API
Filings indexed 114 across all filing types
Latest filing 2026-04-27 Interim / Quarterly Rep…
Country AU Australia
Listing ASX PYC

About PYC THERAPEUTICS LIMITED

https://pyctx.com/

PYC Therapeutics Limited is a clinical-stage company focused on developing precision medicines for patients with rare genetic diseases. The company utilizes a proprietary drug delivery platform that combines naturally derived cell-penetrating peptides with antisense oligonucleotides to create RNA-based therapeutics. This platform is designed to overcome the challenges of delivering large therapeutic molecules into target cells, particularly within the eye and central nervous system. PYC's primary pipeline includes VP-001, a candidate for Retinitis Pigmentosa type 11, and PYC-001, targeting Autosomal Dominant Optic Atrophy. Additionally, the company is advancing programs for Polycystic Kidney Disease. By leveraging its delivery technology, PYC aims to address the underlying genetic causes of diseases that currently lack effective treatment options.

Recent filings

Filing Released Lang Actions
Quarterly Activities/Appendix 4C Cash Flow Report 13 pages 3.5MB
Interim / Quarterly Report Classification · 1% confidence The document is titled “Q1 2026 Shareholder Update” and provides substantive quarterly operational and financial information. It includes actual financial statements (Appendix 4C cash flow report for the quarter ended 31 March 2026) and detailed clinical progress metrics. This is not merely an announcement that a report is available, but the report itself with data, fitting the definition of an Interim / Quarterly Report rather than an earnings teaser or investor presentation. Therefore, the correct classification is IR. Q1 2026
2026-04-27 English
Application for quotation of securities - PYC 6 pages 18.5KB
Share Issue/Capital Change Classification · 1% confidence The document is ASX Appendix 2A – an application for quotation of newly issued securities following exercise of options/convertible securities. It details the number and class of securities to be quoted, issue date, and post-issue capital structure. This is a corporate action related to issuing and quoting additional shares, matching the “Share Issue/Capital Change” category (SHA).
2026-04-27 English
Exercise of Options and Cleansing Notice 2 pages 226.7KB
Share Issue/Capital Change Classification · 1% confidence The document is an ASX announcement by PYC Therapeutics Limited detailing the issuance of 250,000 new ordinary shares upon exercise of unlisted options and providing a cleansing notice under Section 708A of the Corporations Act. It refers to issuing shares, Appendix 2A quotation for the new shares, and compliance statements. This clearly falls under announcements of new share issues / capital structure changes, matching the 'Share Issue/Capital Change' category (Code: SHA).
2026-04-27 English
Orphan Drug Designation Granted for RP11 by EMA 2 pages 220.4KB
Regulatory Filings Classification · 1% confidence The document is a corporate ASX announcement providing a regulatory update about the European Medicines Agency granting Orphan Drug Designation for the company’s drug candidate. It does not report financial results (not an ER or IR), is not a transcript, not a board change, not a dividend notice, not a capital raise, and not a meeting or voting document. It is a general regulatory announcement and thus best fits the fallback category “Regulatory Filings” (RNS).
2026-04-26 English
ADOA Program - SRC Approve Progression to Multi-Dose Study 3 pages 385.8KB
Regulatory Filings
2026-04-14 English
Change in substantial holding 3 pages 243.4KB
Regulatory Filings
2026-03-31 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.